Displaying 1 - 12 of 74
Metabolism, Alcohol & Toxicity
6

Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022

View
Metabolism, Alcohol & Toxicity
6

Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022

View
Metabolism, Alcohol & Toxicity
6

Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022

View
Metabolism, Alcohol & Toxicity
6

Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022

View
Metabolism, Alcohol & Toxicity
6

Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022

View
Metabolism, Alcohol & Toxicity
6

Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022

View
Metabolism, Alcohol & Toxicity
6

Echosens: Enhancing the management of NAFLD patients with FibroScan-based scores - ILC 2021

View
Metabolism, Alcohol & Toxicity
6

Echosens: Enhancing the management of NAFLD patients with FibroScan-based scores - ILC 2021

View
Metabolism, Alcohol & Toxicity
6

Echosens: Enhancing the management of NAFLD patients with FibroScan-based scores - ILC 2021

View
Metabolism, Alcohol & Toxicity
6

Echosens: Enhancing the management of NAFLD patients with FibroScan-based scores - ILC 2021

View
Metabolism, Alcohol & Toxicity
6

Echosens: Enhancing the management of NAFLD patients with FibroScan-based scores - ILC 2021

View
Metabolism, Alcohol & Toxicity
6

Echosens: Enhancing the management of NAFLD patients with FibroScan-based scores - ILC 2021

View